BioPharmX Corporation (NYSE:BPMX) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
BioPharmX Corporation (NYSE:BPMX) lost -5.47 Percent and closed its previous trading session at $0.11. The stock traded with the average Volume of 1.98 Million at the end of last session.
BioPharmX Corporation (NYSE:BPMX) has the Market Capitalization of 13.88 Million. The Stock has its 52-week High of $0.900 and 52-Week Low of $0.110 and it touched its 52-week high on 04/28/17 and 52-Week Low on 11/27/17.
The company reported its last earnings Actual EPS of $-0.05/share. While, the analyst predicted that the company could provide an EPS of $-0.06/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.01/share which shows an Earnings Surprise of 16.7 Percent.
Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated BioPharmX Corporation (NYSE:BPMX) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -30.39% where SMA50 and SMA200 are -48.64% and -72.83% respectively.
The company shows its Return on Assets (ROA) value of -426.9%.
BioPharmX Corporation (NYSE:BPMX) currently has a Weekly Volatility of 9.80% percent while its Monthly Volatility is at 11.32% percent. While talking about Performance of the Stock, BioPharmX Corporation currently has a Weekly performance of -12.09%, monthly performance percentage is -35.34 percent, Quarterly performance is -68.34 percent, 6 months performance shows a percent value of -78.24% and Yearly Performance is -74.47 percent.
BioPharmX Corporation is a specialty pharmaceutical company. The company focuses on the development of novel drug delivery products for women’s health, dermatology and otolaryngology markets. The Company’s product pipeline includes products in categories consists of prescription products, over-the-counter products and dietary supplements. Prescription products in development include molecular iodine pill for the treatment of breast pain associated with fibrocystic breast disease. OTC product pipeline includes a series of medicated bandages, nasal sprays and other products. Supplement product pipeline includes BioPharmX’s breast health pill. Its product candidates include BPX03 a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia and BPX01 a non-lipophilic topical antibiotic for the treatment of acne. BioPharmX Corporation is headquartered in Menlo Park, California.